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Abstract (250 words) 
Objectives: Increased cancer risks have been reported among workers in the rubber manufacturing 
industry employed before the 1960s but it is unclear for workers hired subsequently. The present 
study focused on cancer incidence among rubber workers first employed after 1975 in Sweden and 
the United Kingdom. 
Methods: Two cohorts of rubber workers employed for at least one year were analysed. Standardised 
incidence ratios (SIRs), based on country- and period-specific incidence rates, were analyzed for all 
cancers combined (except non-melanoma skin), bladder, lung, stomach cancer, leukaemia, non-
,ŽĚŐŬŝŶ ?ƐůǇŵƉŚŽŵĂĂŶĚŵƵůƚŝƉůĞmyeloma. Exploratory analyses were conducted for other cancers 
with a minimum of ten cases in both genders combined. 
Results: 16,026 individuals (12,441 men; 3,585 women) contributed to 397,975 person-years of 
observation, with 846 cancers observed overall (437 in United Kingdom, 409 in Sweden). No 
statistically significant increased risk was observed for any site of cancer. A reduced risk was evident 
for all cancers combined (SIR=0.83, 95%CI (0.74; 0.92)), lung cancer (SIR=0.74, 95%CI (0.59; 0.93)), 
non-,ŽĚŐŬŝŶ ?ƐůǇŵƉŚŽŵĂ (SIR=0.67, 95%CI (0.45; 1.00)), and prostate cancer (SIR=0.77, 95%CI (0.64; 
0.92)). For stomach cancer and multiple myeloma, SIRs were 0.93 (95%CI (0.61; 1.43)) and 0.92 (95%CI 
0.44; 1.91), respectively. No increased risk of bladder cancer was observed (SIR=0.88, 95%CI (0.61; 
1.28)). 
Conclusions: No significantly increased risk of cancer incidence was observed in the combined cohort 
of rubber workers first employed since 1975. Continued surveillance of the present cohorts is required 
to confirm absence of long-term risk and confirmatory findings from other cohorts would be 
important. 
Keywords: rubber, occupational exposure, cohort study, cancer, incidence 
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What this paper adds:  
x Occupational exposure in the rubber manufacturing industry is an IARC group 1 human 
carcinogen. But recent studies suggested that, following improvement in occupational 
hygiene, cancer risks were no longer observable. 
x In a prospective cohort of 16,026 workers employed since 1975 in the rubber manufacturing 
industry in United Kingdom and Sweden, and followed for 23 years on average, no consistent 
increased cancer incidence was observed.  
x Although the findings from this study are reassuring, continued surveillance of the present 
cohorts is required to confirm absence of long-term risk. 
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Introduction 
  Occupational exposure in the rubber manufacturing industry, i.e. production of tyres and 
general rubber goods and process of re-treading, is an IARC group 1 human carcinogen 1. The IARC 
evaluation, based mainly on observational studies on workers mostly employed before the 1960s, 
concluded there was sufficient evidence of an increased risk of bladder cancer, leukaemia, stomach, 
lung cancer and lymphoma. The carcinogens involved in these excesses are as yet unknown but 
exposure to aromatic amines, and solvents have been suspected to play a role 2.  
 The rubber manufacturing industry has undergone radical technological changes since the 
1950s, entailing major reductions in rubber dust 3 and fume exposure and the decrease of known 
carcinogenic agents like benzene and beta naphtylamine, although others, such as nitrosamines, are 
still present. A recent study from five European countries on 38,457 workers employed since 1975, 
with nearly a million person-years, showed no increased of cancer mortality for bladder cancer, 
leukaemia, lung cancer and lymphoma 4. However, this study suggested an increased risk of stomach 
cancer and multiple myeloma in the general rubber goods (GRG) sector, but not in the tyre sector. 
These findings were driven by an increased risk in one of the five contributing cohorts.  
  Incidence data were also collected in the United Kingdom and Sweden, part of the European 
cohorts, and provide a helpful complementary evaluation of the association between occupational 
exposure in the rubber manufacturing industry and cancer. While easier to collect and widely available 
in several countries, mortality data is a heterogeneous mix of cancers diagnosed in the preceding years 
with various latencies between exposure and outcome. In addition, incidence data are less affected 
by misclassification problems as compared to mortality data and are not affected by trends in 
curability of some forms of cancers 5.  
  The present study reports data on incidence of cancer in the United Kingdom and Sweden 
with two objectives: first, to confirm whether no increased risk of cancer was also observed for cancer 
incidence; second, to evaluate whether the suspected increased risk of stomach cancer and of multiple 
myeloma were also present in cancer incidence.  
Material and methods 
  A protocol specifying inclusion criteria and a detailed statistical analysis plan was prepared 
between local principal investigators of the present study prior to data analysis. Details on the 
methods and mortality data have been published elsewhere 4. The initial cohort consisted of rubber 
workers employed since 1975 for at least one year in rubber manufacturing industries in Germany, 
Italy, Poland, Sweden and the United Kingdom, but incidence data were available only in Sweden and 
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the United Kingdom. In Sweden, data from a cohort of workers first employed in 1975 or later were 
extracted from an initial cohort using personnel records from Swedish rubber manufacturing plants, 
situated in 11 different places all over the country. Vital statistics were obtained from Statistics 
Sweden and with linkage to the Swedish cancer registry, information on up to two tumours per worker 
were extracted. In the United Kingdom, an initial cohort of workers employed for the first time in the 
rubber manufacturing industry within the period 1982-1991 was established from 41 rubber factories 
in England, Wales and Scotland. Incidence of cancer was obtained from the UK Health and Social Care 
Information Centre. For both Sweden and United Kingdom, the follow-up with vital statistics and 
cancer incidence was conducted up to 31st December 2011. 
 Primary, secondary and exploratory outcomes were defined in the study protocol, prior to 
ƐƚƵĚǇĐŽŶĚƵĐƚ ?ďĂƐĞĚŽŶƚŚĞ/Z ?ƐĞǀĂůƵĂƚŝŽŶĂŶĚŽŶƚŚĞƐƚƌĞŶŐƚŚŽĨĂƐƐŽĐŝĂƚŝŽŶĂƐƌĞƉŽƌƚĞĚŝŶƚŚĞ
systematic review of Kogevinas et al 1998 6. The primary outcomes of interest were therefore 
incidence of bladder cancer and lung cancer. Secondary outcomes were incidence of all cancers 
combined (excluding non-melanoma skin cancer), stomach cancer, leukaemia, multiple myeloma and 
non-Hodgkin ?Ɛ lymphoma (NHL). Data from other cancer sites, not previously defined, were also 
included in exploratory analysis but only if more than ten cases were observed in men or women 
combined. Non-melanoma skin cancers and benign neoplasms were excluded from the analysis. The 
list of international classification of diseases (ICD) codes used in the present article is reported in 
supplementary table 1 (S-Table 1). ICD-7 and ICD-8 codes were used in Sweden, whereas ICD-9 and 
ICD-10 codes were used in the United Kingdom. 
 The observed numbers of cases for each cancer site were compared with the expected 
numbers calculated on the basis of national gender-, age- and period-specific incidence rates. Five-
year age groups were used for age and time period. Reference rates were obtained from the CI5+ 
Database (Revision of February 2014). In Sweden, national reference rates were obtained. In the UK, 
reference rates were obtained separately for Scotland and England/Wales. Rates of Scotland and 
England/Wales were pooled as all UK factories were located in these three areas of United Kingdom. 
Patients were followed from one year after date of hire until the earliest of the following: date of 
death, date of loss to follow-up/emigration or right censored at 31st of December 2011. For each 
country, standardized incidence ratios (SIRs, i.e., the ratio of observed to expected cases) were 
calculated together with their confidence intervals based on the Poisson distribution of observed 
cases 7 8. Country-specific SIRs were combined using random-effects models 9, which take into account 
potential heterogeneity among cohorts.  
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  Measures of heterogeneity were reported using I2 statistics 10 as well as tests for 
ŚĞƚĞƌŽŐĞŶĞŝƚǇďĂƐĞĚŽŶŽĐŚƌĂŶ ?ƐYstatistic although this test is known for having poor statistical 
power 11. In a sensitivity analysis, an induction-latency period of ten years was applied. 
 The role of the duration of employment on the risk of all cancers combined was investigated 
in a Poisson model with a smooth function of duration of employment as an explanatory variable, and 
ƚŚĞůŽŐĂƌŝƚŚŵŽĨƚŚĞĞǆƉĞĐƚĞĚŶƵŵďĞƌŽĨĐĂŶĐĞƌƐĂƐ ‘ŽĨĨƐĞƚ ? ?Duration of employment was modelled 
with cubic natural splines and three degrees of freedom. Cutpoints (knots) of duration of employment 
were built from duration of employment of subjects diagnosed with cancer, such that at least eight 
cases occurred between two points. This enables a stable estimation of SIR while keeping enough 
points for modelling the splines for the parameter of duration. Because duration could not be 
estimated for several workers still employed at the last job history update, this analysis was restricted 
to the subset of 8,100 workers (51% of the cohort) with complete job history. 
  All data were anonymised prior to statistical analysis. This study did not require a specific IRB 
approval as performed on fully anonymised secondary data. P-values below 5% were considered as 
statistically significant. 
Results 
 A total of 16,026 workers (12,441 men and 3,585 women) were included in the present study 
(Table 1). The median follow-up was 23 years, contributing to a total of 397,975 person-years of 
observation. The majority of workers (77.6%) were men; more women were recruited in Sweden. 
Overall, 846 malignant cancer cases (excluding non melanoma skin cancers) were observed during the 
follow-up, 437 in United Kingdom and 409 in Sweden.  
  Table 2 shows observed cases and SIRs for different cancer sites for Sweden, the United 
Kingdom and both countries combined. Based on 45 cases observed during the follow-up, the risk of 
bladder cancer was SIR=0.88 (95% CI (0.61; 1.28)) with no evidence of heterogeneity between 
countries. This absence of increased risk for bladder cancer remained when stratified by gender (S-
Table 2 and S-Table 3), although the analysis restricted to women is based on less than ten cases from 
most outcomes. The risk of lung cancer was based on 82 cases and was significantly decreased in 
rubber workers as compared to the general population with a SIR of 0.74 (95% CI (0.59; 0.93)) with no 
heterogeneity between countries.  
 Concerning secondary outcomes, a statistically significant decrease was observed for all 
cancer combined (SIR= 0.83, 95% CI (0.74; 0.92)) and for non-,ŽĚŐŬŝŶ ?Ɛůymphoma (SIR = 0.67, 95% CI 
(0.45; 1.00)). Risks of other secondary outcomes were neither significantly increased nor significantly 
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decreased. At country level, the risk of all cancer combined was significantly decreased in both Sweden 
and the United Kingdom. In addition the risk of leukaemia was significantly decreased in Sweden. 
  Analysis of exploratory outcomes revealed no significantly increased risk for any cancer site 
when both countries were combined. A significantly decreased risk of prostate cancer was found: SIR 
= 0.77 (95% CI (0.64; 0.92)) based on 123 cases.  
Results for cancers appearing after an induction-latency period of ten years are shown in S-
table 4. This analysis covered 15,466 subjects (7,131 in Sweden and 8,335 in the UK) representing 
overall 240,561 person-years of observation. Results remained close to those of the main analysis. 
Results of analyses stratified by gender are given in S-table 2 (men) and S-table 3 (women). In 
men, there were significantly reduced SIRs for lung cancer and prostate cancer. In women, there was 
a significantly reduced SIR for all cancers combined, and SIRs below unity for most cancers. The only 
significantly increased SIR was for melanoma, SIR 1.65 (95% CI (1.04; 2.60). It was based on 21 cases, 
of which 20 occurred in Sweden (table S-3). This association was not found in men, neither in UK nor 
in Sweden; the SIR was 0.74 (95% CI (0.44; 1.24)) and was based on 30 cases (19 in Sweden and 11 in 
the United Kingdom). 
The risk of all cancers combined (except non-melanoma skin cancer) was further investigated 
in a Poisson regression with a spline function applied to the duration of employment (Figure 1). This 
analysis was restricted to the 8,100 workers (4,005 in the UK and 4,095 in Sweden) with complete 
information on job history, i.e. representing 51% of the cohort. When compared to the rest of the 
cohort, these workers only slightly differed with more men (81.2% vs 73.5% for complete vs 
incomplete job history) and older on average (mean age at recruitment 29.7 vs 26.0 for complete vs 
incomplete job history). For employment durations under 20 years the risk of cancer remained close 
to 0.8, and then the trend went up until about 1. 
Discussion 
  In this cohort of workers employed for at least one year in the rubber manufacturing industry 
first employed since 1975 in two European countries, there was no consistent indication of an 
increased risk of cancer incidence among the cancer sites pre-identified as primary or secondary 
outcomes of interest, i.e. all cancers combined, and site-specific incidence for bladder, lung, stomach, 
leukaemia, myeloma and non-,ŽĚŐŬŝŶ ?Ɛ ůǇŵƉŚŽŵĂ ?In addition, none of the exploratory outcomes 
had their risk significantly increased when both genders were combined. From the Poisson regression, 
the risk of all cancers combined remained relatively stable with duration of employment with a slight 
increase after 20 years; confident interpretation of these regression findings is not possible.  
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  A statistically significant increased risk of melanoma was identified, but it was limited to 
Swedish women. With such an increased only observed in one country and one gender, and because 
rubber manufacture worker is not an outdoor employment, a difference in job exposure is unlikely to 
offer a good explanation for the increase. Non-melanoma skin cancer incidence is a tentative marker 
of solar exposure, but is markedly affected by access to screening and by registration bias. Hence, 
there is no solid data to help interpret the increase in melanoma incidence in Swedish women by 
either a role of non-occupational or occupational solar exposure, an overdiagnosis in women within 
the health care system in the rubber factory areas, or a chance finding. 
  Analysis of cancer mortality data in five European countries also did not report an increased 
risk of cancer 4. Results on incidence for Sweden and United Kingdom were in the same order of 
magnitude as results based on mortality for all sites except multiple myeloma in United Kingdom. The 
SMR for multiple myeloma deaths in the UK cohort was 2.26 (95% CI (0.97; 4.44)) for both genders, 
whereas in the present report on incidence the corresponding SIR was 1.04 (95% CI (0.45; 2.05)). In 
addition, the observed increased risk in the mortality study was observed only in men in the general 
rubber goods sector, which represents only 36% of workers in the UK cohort. This suggests that the 
initially observed high multiple myeloma mortality observed in United Kingdom could be a chance 
finding, but specific exposure  ?related explanations cannot be fully excluded. Risk of stomach cancer 
mortality was high in Poland in the mortality study. Similarly to previously reported mortality findings, 
in United Kingdom and Sweden the incidence of stomach cancer remained not increased. 
  dŚĞĂďƐĞŶĐĞŽĨŝŶĐƌĞĂƐĞĚƌŝƐŬŽĨĐĂŶĐĞƌŝŶƚŚĞƉƌĞƐĞŶƚƐƚƵĚǇ ?ŝŶĐŽŶƚƌĂƐƚƚŽĨŝŶĚŝŶŐƐŝŶƚŚĞ ?ŽůĚ ”
rubber industry, could be the result of changes in the rubber manufacturing industry. Data collected 
within the European project ExAsRub (improved EXposure ASsessment for prospective cohort studies 
and exposure control in the RUBber manufacturing industry), which combined comparable exposure 
information in rubber industry across Europe in a database, are in line with this hypothesis by showing 
a continuous decreasing time trends of inhalable dust from 1975 to 2005 3. 
  The study has a number of limitations. First, there was a lack of accurate data on duration of 
employment in the rubber industry, due to no recent update of job histories which limited the analysis 
of long-term exposures. Secondly, the cohort of workers employed since 1975 in these two countries 
is young with an average age at the end of follow-up of 50 years, hence the magnitude of impact of 
cancer in these populations could only be partially evaluated and longer follow-up would be needed 
to evaluate the potential impact of these occupational exposures on entire life. Thirdly, as for most 
studies which evaluated the impact of occupational exposure in the rubber manufacturing industry 
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and risk of cancer 1, no behavior data were available and it was therefore not possible to adjust for 
tobacco smoking and other potential confounders. 
  The findings of no observed increased risk of cancer in these cohorts from rubber 
manufacturing industry are reassuring. However, it is recommended that these cohorts continue to 
be monitored regularly to investigate if absence of increased cancer risk is present after longer follow-
up, and long-term positive effects of industrial hygiene improvements are maintained. Confirmatory 
findings from other cohorts would also be important.  
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Table 1. Characteristics of the two European cohorts of workers first employed in the rubber manufacturing industry since 1975 
 Sweden UK 
Number of workers 7424 8602 
Number of factories 11 41 
Follow-up (Median, years) 21.7 24.1 
Number of deaths 376 546 
Number of cancer cases 409 437 
Gender (% men) 66.3% 87.4% 
Type of industry (%Tyre/%GRG/%Other*) 5.5/32.2/62.4 51.0/36.2/12.8 
Age at hiring (Median, IQR) 25 (20; 35) 25 (21; 33) 
Duration of employment (Median, IQR) 4.6 (2.2; 10.3**) 4.9 (2.6; 12.7) 
Date of first recruitment 01/01/1975 01/01/1982 
Date of last follow-up 31/12/2011 31/12/2011 
Date of last job history update 01/07/2002 - 31/12/2011 (4005 subjects/47%) 
- Variable between 1988 and 1995 (4597 subjects/53%) 
% Still employed at last job history update 44.8% 
 
- Last job history update 2011: 14.5% among 4005 subjects 
Person-years by induction-latency: <20 vs. A? 20 years 133,629 vs. 41,138 166,688 vs. 56,520 
Person-years by duration of employment: < 5 vs. A? 5 years 102,837 vs. 71,930 131,592 vs. 91,616 
GRG: factories producting general rubber goods; Tyre: factories producing tyres; IQR: inter-quartile range; UK: United Kingdom 
*Other includes mixed factories (both tyre and GRG) 
**: not estimable as more than 25% of workers were still employed at the last job history update  
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Table 2. Observed cases and standardised incidence ratios (SIRs) among 16,026 workers first employed in the European rubber manufacturing industry 
since 1975, by country. 
  Sweden (N=7,424; PY=174,767) United Kingdom (N=8,602; PY=223,208) Combined (N=16,026; PY=397,975) 
Cancer sites Observed SIR (95% CI) Observed  SIR (95% CI) Observed  SIR (95% CI) 
Primary outcomes       
  Bladder 23 1.15 (0.73, 1.72) 22 0.68 (0.42, 1.02) 45 0.88 (0.61, 1.28) 
  Lung 30 0.78 (0.63, 1.34) 52 0.72 (0.53, 0.94) 82 0.74 (0.59, 0.93) 
Secondary outcomes       
  All cancers combined (except skin) 409 0.90 (0.81, 0.99) 437 0.76 (0.69, 0.85) 846 0.83 (0.74, 0.92)* 
  Stomach 8 0.87 (0.37, 1.71) 16 0.97 (0.55, 1.57) 24 0.93 (0.61, 1.43) 
  Leukaemia 4 0.34 (0.09, 0.88) 15 0.96 (0.54, 1.58) 19 0.79 (0.48, 1.28) 
  Non-,ŽĚŐŬŝŶ ?ƐůǇŵƉŚŽŵĂ 10 0.64 (0.31, 1.18) 18 0.69 (0.41, 1.08) 28 0.67 (0.45, 1.00) 
  Multiple myeloma 1 0.19 (<0.01, 1.04) 8 1.04 (0.45, 2.05) 9 0.92 (0.44, 1.91) 
Exploratory outcomes**       
  Brain and central nervous system 15 0.90 (0.50, 1.49) 10 0.65 (0.31, 1.20) 25 0.79 (0.52, 1.21) 
  Colon, rectum and anus 48 1.06 (0.78, 1.41) 37 0.55 (0.39, 0.75) 85 0.77 (0.49, 1.22)* 
  Kidney 11 0.87 (0.43, 1.55) 16 0.85 (0.49, 1.39) 27 0.86 (0.57, 1.29) 
  Larynx 3 - 7 0.91 (0.37, 1.87) 10 0.98 (0.49, 1.96) 
  Melanoma 39 1.30 (0.92, 1.78) 12 0.43 (0.22, 0.75) 51 0.79 (0.37, 1.70)* 
  Oesophagus 4 - 14 0.82 (0.45, 1.37) 18 0.84 (0.51, 1.39) 
  Oral cavity and pharynx 13 1.18 (0.63, 2.02) 19 0.93 (0.56, 1.44) 32 1.02 (0.71, 1.48) 
  Pancreas 8 0.88 (0.38, 1.74) 9 0.72 (0.33, 1.37) 17 0.80 (0.47, 1.34) 
  Prostate 70 0.80 (0.63, 1.02) 53 0.72 (0.54, 0.94) 123 0.77 (0.64, 0.92) 
  Testis 13 1.26 (0.67, 2.16) 11 0.61 (0.32, 1.04) 26 0.87 (0.53, 1.45) 
  Breast 51 0.82 (0.60, 1.08) 38 1.04 (0.67, 1.29) 89 0.91 (0.73, 1.13) 
  Endometrial 6 0.69 (0.25, 1.50) 5 1.00 (0.32, 2.33) 11 0.82 (0.42, 1.58) 
  Ovary 9 1.14 (0.52, 2.16) 7 1.23 (0.50, 2.54) 16 1.18 (0.69, 2.02) 
Statistically significant associations are in bold 
N: number of workers; PY: Person-years; SIR: Standardized Incidence Ratio; 95%CI: 95 % confidence interval 
* Significant heterogeneity between the two countries (p<0.05) 
** Results of exploratory analyses with less than 5 cases observed were not reported  
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Legend of Figure 
 
Figure 1. Analysis of risk of cancer from two cohorts of European rubber-manufacturing workers by duration of employment among 8,100 workers with 
complete follow-up information. The horizontal dotted line corresponds to the global SIR for all cancers except skin. The plain black lines represent the 
spline curve of SIR by duration of employment (bold line) with its 95% confidence interval (plain lines). 
 
 
15 
 
Appendix 
S-Table 1. List of ICD codes used for classifying cancers sites in the two countries 
Cancer sites ICD7 ICD8 ICD9 ICD10 
Primary outcomes     
  Bladder 181 188 188 C67 
  Lung 162.0, 162.1, 
162.8 
162 162 C33-C34 
Secondary outcomes     
  All cancers combined 
(except skin) 
140-207 excl. 191 140-209 excl. 
173 
140-208 excl. 
173 
C00-C97 excl. 
C44 
  Stomach 151 151 151 C16 
  Leukaemia 204 204-207 204-208 C91-C95 
  Non-Hodgkin's 
lymphoma 
200, 202 200, 202  200, 202 C82-C86  
  Multiple myeloma 203 203 203 C90  
Exploratory outcomes     
  Brain and central 
nervous system 
193 191, 192 171, 191, 
192 
C47, C70-C72 
  Colon, rectum and anus 153, 154 153, 154 153, 154 C18-C21 
  Kidney 180 189 189 C64-66, C68 
  Larynx 161 161 161 C32 
  Melanoma 190 172 172 C43 
  Oesophagus 150 150 150 C15 
  Oral cavity and pharynx 140-148 140-149 140-149 C00-C14 
  Pancreas 157 157 157 C25 
  Prostate 177 185 185 C61 
  Testis 178 186 186 C62 
  Breast 170 174 174 C50 
  Ovary 175 183 183 C56 
ICD: International Classification of Disease 
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S-Table 2. Observed cases and standardised incidence ratios (SIRs) among 12,441 male workers 
first employed in the European rubber manufacturing industry since 1975, by country. 
  Sweden (N=4,923; 
PY=116,627) 
United Kingdom 
(N=7518; PY=194,797) 
Combined (N=12,441; 
PY=311,424) 
Cancer sites Observed SIR (95% 
CI) 
Observed  SIR (95% 
CI) 
Observed  SIR (95% 
CI) 
Primary outcomes       
  Bladder 19 1.10 
(0.66, 
1.71) 
20 0.66 (0.40, 
1.01) 
39 0.84 (0.59, 
1.20) 
  Lung 20 0.91 
(0.56, 
1.41) 
45 0.73 (0.53, 
0.97) 
66 0.78 (0.60, 
1.00) 
Secondary 
outcomes 
      
  All cancers 
combined (except 
skin) 
267 0.92 
(0.82, 
1.04) 
349 0.74 (0.67, 
0.83) 
616 0.83 (0.71, 
0.96)* 
  Stomach 5 0.70 
(0.23, 
1.64) 
16 1.05 (0.60, 
1.71) 
21 0.96 (0.61, 
1.53) 
  Leukaemia 3 0.35 
(0.07, 
1.03) 
13 0.93 (0.49, 
1.59) 
16 0.79 (0.47, 
1.35) 
  Non-,ŽĚŐŬŝŶ ?Ɛ
lymphoma 
8 0.70 
(0.30, 
1.39) 
18 0.78 (0.46, 
1.23) 
26 0.76 (0.50, 
1.14) 
  Multiple myeloma 1 0.25 
(0.01, 
1.41) 
5 0.75 (0.24, 
1.74) 
6 0.66 (0.26, 
1.66) 
Exploratory 
outcomes** 
      
  Brain and central 
nervous system 
10 0.91 
(0.44, 
1.68) 
9 0.65 (0.30, 
1.24) 
19 0.78 (0.48, 
1.27) 
  Colon, rectum and 
anus 
35 1.12 
(0.78, 
1.56) 
31 0.53 (0.36, 
0.75) 
66 0.77 (0.46, 
1.30)* 
  Kidney 10 1.02 
(0.49, 
1.88) 
16 0.94 (0.54, 
1.53) 
26 0.97 (0.64, 
1.47) 
  Larynx 3 - 7 0.95 (0.38, 
1.95) 
10 1.04 (0.52, 
2.08) 
  Melanoma 19 1.02 
(0.61, 
1.59) 
11 0.48 (0.24, 
0.85) 
30 0.74 (0.44, 
1.24) 
  Oesophagus 3 - 14 0.88 (0.48, 
1.48) 
17 0.87 (0.52, 
1.46) 
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  Oral cavity and 
pharynx 
13 1.52 
(0.81, 
2.60) 
17 0.89 (0.52, 
1.43) 
30 1.12 (0.77, 
1.64) 
  Pancreas 4 - 8 0.74 (0.32, 
1.47) 
12 0.72 (0.38, 
1.34) 
  Prostate 70 0.80 
(0.63, 
1.02) 
53 0.72 (0.54, 
0.94) 
123 0.77 (0.64, 
0.92) 
  Testis 13 1.26 
(0.67, 
2.16) 
11 0.61 (0.32, 
1.04) 
26 0.87 (0.53, 
1.45) 
Statistically significant associations are in bold 
N: number of workers; PY: Person-years; SIR: Standardized Incidence Ratio; 95%CI: 95 % confidence 
interval 
* Significant heterogeneity between the two countries (p<0.05) 
** Results of exploratory analysis with less than 5 cases observed were not reported 
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S-Table 3. Observed cases and standardised incidence ratios (SIRs) among 3,585 female workers 
first employed in the European rubber manufacturing industry since 1975, by country. 
  Sweden (N=2,501 ; 
PY= 58,140) 
United Kingdom 
(N=1,084; PY= 28,411) 
Combined (N=3,585; 
PY=86,551) 
Cancer sites Observed SIR (95% 
CI) 
Observed  SIR (95% 
CI) 
Observed  SIR (95% 
CI) 
Primary outcomes       
  Bladder 4 1.46 
(0.40, 
3.75) 
2 0.95 (0.12, 
3.44) 
6 1.26 
(0.50, 
3.27) 
  Lung 5 0.50 
(0.16, 
1.17) 
6 0.65 (0.24, 
1.42) 
11 0.58 
(0.30, 
1.12) 
Secondary 
outcomes 
      
  All cancers 
combined (except 
skin) 
142 0.85 
(0.72, 
1.00) 
88 0.84 (0.67, 
1.03) 
230 0.85 
(0.74, 
0.97) 
  Stomach 3 1.42 
(0.29, 
4.15) 
0 0.00 (0.00, 
2.81) 
3 1.05 
(0.29, 
3.76) 
  Leukaemia 1 0.32 
(0.01, 
1.81) 
2 1.18 (0.14, 
4.28) 
3 0.82 
(0.19, 
3.45) 
  Non-,ŽĚŐŬŝŶ ?Ɛ
lymphoma 
2 0.48 
(0.06, 
1.72) 
0 0.00 (0.00, 
1.16) 
2 0.30 
(0.06, 
1.49) 
  Multiple myeloma 0 0.00 
(0.00, 
2.63) 
3 3.09 (0.64, 
9.02) 
3 2.15 
(0.60, 
7.67) 
Exploratory 
outcomes** 
      
  Brain and central 
nervous system 
5 0.88 
(0.29, 
2.06) 
1 - 6 0.85 
(0.34, 
2.14) 
  Colon, rectum and 
anus 
13 0.93 
(0.50, 
1.60) 
6 0.68 (0.25, 
1.47) 
19 0.85 
(0.52, 
1.38) 
  Kidney 1 - 0 - 1 - 
  Larynx 0 - 0 - 0 - 
  Melanoma 20 1.75 
(1.07, 
2.71) 
1 - 21 1.65 
(1.04, 
2.60) 
  Oesophagus 1 - 0 - 1 - 
  Oral cavity and 
pharynx 
0 - 2 - 2 - 
  Pancreas 1 - 4 - 5 1.26 
(0.45, 
3.54) 
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  Breast 51 0.82 
(0.60, 
1.08) 
38 1.04 (0.67, 
1.29) 
89 0.91 
(0.73, 
1.13) 
  Endometrial 6 0.69 
(0.25, 
1.50) 
5 1.00 (0.32, 
2.33) 
11 0.82 
(0.42, 
1.58) 
  Ovary 9 1.14 
(0.52, 
2.16) 
7 1.23 (0.50, 
2.54) 
16 1.18 
(0.69, 
2.02) 
Statistically significant associations are in bold 
N: number of workers; PY: Person-years; SIR: Standardized Incidence Ratio; 95%CI: 95 % confidence 
interval 
* Significant heterogeneity between the two countries (p<0.05) 
** Results of exploratory analysis with less than 5 cases observed were not reported 
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S-Table 4. Observed cases and standardised incidence ratios (SIRs) among 15,466 workers first 
employed in the European rubber manufacturing industry since 1975, by country, with a 10-years 
induction-latency period. 
  Sweden (N=7,131; 
PY=102,089) 
United Kingdom 
(N=8,335; PY=138,472) 
Combined (N=15,466; 
PY=240,561) 
Cancer sites Observed SIR (95% 
CI) 
Observed  SIR (95% 
CI) 
Observed  SIR (95% 
CI) 
Primary outcomes       
  Bladder 18 1.06 (0.63, 
1.67) 
16 0.57 (0.33, 
0.93) 
34 0.79 (0.52, 
1.21) 
  Lung 25 0.81 (0.60, 
1.37) 
46 0.74 (0.55, 
0.99) 
71 0.77 (0.60, 
0.98) 
Secondary 
outcomes 
      
  All cancers 
combined (except 
skin) 
332 0.89 
(0.79, 
0.99) 
367 0.76 (0.68, 
0.84) 
699 0.82 (0.73, 
0.91)* 
  Stomach 4 0.54 (0.15, 
1.38) 
11 0.81 (0.40, 
1.44) 
15 0.73 (0.42, 
1.27) 
  Leukaemia 1 0.11 
(<0.01, 
0.62) 
14 1.12 (0.61, 
1.88) 
15 1.02 (0.59, 
1.76) 
  Non-,ŽĚŐŬŝŶ ?Ɛ
lymphoma 
9 0.72 (0.33, 
1.36) 
17 0.79 (0.46, 
1.26) 
26 0.76 (0.51, 
1.15) 
  Multiple myeloma 1 0.22 (0.01, 
1.22) 
7 1.03 (0.41, 
2.12) 
8 0.90 (0.41, 
1.97) 
Exploratory 
outcomes** 
      
  Brain and central 
nervous system 
9 0.70 (0.32, 
1.34) 
7 0.60 (0.24, 
1.24) 
16 0.66 (0.38, 
1.12) 
  Colon, rectum 
and anus 
39 1.01 (0.72, 
1.38) 
31 0.52 (0.36, 
0.74) 
70 0.74 (0.47, 
1.16)* 
  Kidney 8 0.77 (0.33, 
1.52) 
14 0.85 (0.47, 
1.43) 
22 0.82 (0.53, 
1.29) 
  Larynx 2 - 7 1.07 (0.43, 
2.21) 
9 1.05 (0.50, 
2.20) 
  Melanoma 28 1.24 (0.82, 
1.79) 
11 0.47 (0.24, 
0.85) 
39 0.82 (0.43, 
1.58)* 
  Oesophagus 3 - 12 0.78 (0.40, 
1.37) 
15 0.79 (0.46, 
1.38) 
  Oral cavity and 
pharynx 
10 1.13 (0.54, 
2.09) 
15 0.83 (0.47, 
1.38) 
25 0.94 (0.62, 
1.43) 
  Pancreas 6 0.81 (0.30, 
1.76) 
7 0.64 (0.26, 
1.32) 
13 0.71 (0.39, 
1.30) 
  Prostate 66 0.82 (0.64, 
1.04) 
51 0.72 (0.54, 
0.94) 
117 0.78 (0.64, 
0.93) 
  Testis 6 1.05 (0.39, 
2.29) 
8 0.61 (0.26, 
1.19) 
14 0.76 (0.43, 
1.36) 
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  Breast 43 0.86 (0.62, 
1.16) 
29 0.98 (0.59, 
1.27) 
72 0.91 (0.71, 
1.15) 
  Endometrial 6 0.82 (0.30, 
1.78) 
4 - 10 0.85 (0.43, 
1.71) 
  Ovary 5 0.85 (0.28, 
1.99) 
5 1.10 (0.36, 
2.57) 
10 0.97 (0.48, 
1.95) 
Statistically significant associations are in bold 
N: number of workers; PY: Person-years; SIR: Standardized Incidence Ratio; 95%CI: 95 % confidence 
interval 
* Significant heterogeneity between the two countries (p<0.05) 
** Results of exploratory analysis with less than 5 cases observed were not reported 
 
 
